Recombinant Cynomolgus Monkey IL-17RA/IL-17R His Protein, CF

Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein (Catalog # 11342-IR) has a molecular weight (MW) of 50.1 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (e.g. Glycosylation).

Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein (Catalog #1 1342-IR) inhibits IL-17-induced IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.010‑0.100 µg/mL in the presence of 10.0 ng/mL Recombinant Human IL‑17 (7955-IL).

2 μg/lane of Recombinant Cynomolgus Monkey IL-17RA/IL-17R His-tag Protein (Catalog # 11342-IR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-67 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey IL-17RA/IL-17R His Protein, CF Summary

• Additional Information: His-tag, Analyzed by SEC-MALS
• Details of Functionality: Measured by its ability to inhibit IL-17-induced IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.010‑0.100 µg/mL in the presence of 10.0 ng/mL Recombinant Human IL‑17 (Catalog # 7955-IL).
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey IL-17RA/IL-17R protein
  Leu33-Trp320, with a C-terminal 6-His tag
• Accession #: XP_005568119.1
• N-terminal Sequence: Leu33
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 34 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 59-67 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey IL-17RA/IL-17R His Protein, CF

• CD217 antigen
• CD217
• Cdw217
• CDw217interleukin 17 receptor
• hIL-17R
• IL-17 R
• IL-17 RA
• IL-17 receptor A
• IL17RA
• IL-17RA
• IL-17RAMGC10262
• IL17Rinterleukin-17 receptor A
• interleukin 17 receptor A

Background

IL-17 R, also known as IL-17 RA, is a 120 kDa type I transmembrane glycoprotein protein that plays a central role in inflammatory responses (1-3). Mature mouse IL‑17 R consists of a 291 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 521 aa cytoplasmic domain (4). The cytoplasmic domain contains a region homologous to the TIR domain of the TLR/IL-1 R family (5).  Within the extracellular domain, cynomolgus monkey IL-17RA shares 95% sequence identity with human IL-17RA. While the expression of IL-17 is restricted to activated T cells, IL-17 R exhibits a broad tissue distribution (4). Even in the absence of ligand, IL-17 R exists on the cell surface as a multimer (6). IL-17 R can bind IL-17 but must associate with IL-17 RC to transduce signals (7, 8). Interestingly, human IL-17 R does not appear to form productive complexes with mouse IL-17 RC (8). The IL-17 R can also signal in response to IL-17F (9). IL-17 R ligation promotes T cell activation and the production of IL-6, G-CSF, SCF, and multiple pro‑inflammatory chemokines (4, 7, 9, 10). IL-17A and IL-17F synergize with TNF-alpha in the induction of CXCL1, G-CSF, and IL-6 (9, 11). This effect requires the presence of both TNF RI and TNF RII (9). IL-17 interactions with IL-17 R also inhibit the TNF-alpha induced up-regulation of fibroblast CCL5 and VCAM-1 (11). CCL5 and VCAM-1 induced effects are differentially sensitive to blockade with IL-17 R specific antibodies, suggesting that IL-17 R triggers divergent intracellular signals (11). In vivo, IL‑17 R activity is important for increased generation of neutrophils and their recruitment to sites of inflammation (10, 12, 13). IL-17 R is required for host defense against microbial infection and for the progression of arthritis from inflammation to destructive joint erosion (10, 13).

1. Iwakura, Y. and H. Ishigame (2006) J. Clin. Invest. 116:1218.
2. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
3. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
4. Yao, Z. et al. (1995) Immunity 3:811.
5. Novatchkova, M. et al. (2003) Trends Biochem. Sci. 28:226.
6. Kramer, J.M. et al. (2006) J. Immunol. 176:711.
7. Hymowitz, S.G. et al. (2001) EMBO J. 20:5332.
8. Toy, D. et al. (2006) J. Immunol. 177:36.
9. McAllister, F. et al. (2005) J. Immunol. 175:404.
10. Ye, P. et al. (2001) J. Exp. Med. 194:519.
11. Schnyder, B. et al. (2005) Cytokine 31:191.
12. Tan, W. et al. (2006) J. Immunol. 176:6186.
13. Lubberts, E. et al. (2005) J. Immunol. 175:3360.

Bioinformatics

• Uniprot:
  • XP_005568119.1()